FATTY LIVER DISEASE (FLD)
Characteristics of Normal and Fatty Liver Disease Tissues

Over 20+ years of pharmacokinetic studies, Sekisui XenoTech has accumulated normal and diseased tissues representing FLD with or without history of alcohol consumption and steatohepatitis in its Research Biobank...

Cellular & CYP Composition

**Hepatocytes 60-80%**
Non-parenchymal 20-40%:
- Endothelial ~50%, Kupffer cells ~25%,
- Lymphocytes ~25%, Biliary cells ~5%,
- Stellate <1%

Hepatology Vol 43, S1 Pages S54-S62

Non-alcoholic Fatty Liver Disease (NAFLD)
1) Spectrum of fatty liver disease without history of significant alcohol consumption.
2) Steatosis to steatohepatitis and steatohepatitis with cirrhosis.
3) The liver contains >5% fat by weight.

NAFLD in the US: 10-46%

Non-alcoholic Steatohepatitis (NASH) in the US: 3-5%
1) Hepatic steatosis.
2) Inflammation with hepatocyte injury (ballooning).
3) With or without fibrosis.

NASH progresses to cirrhosis in 20% of patients; Liver-related death occurs in up to 12% of patients over a 10-year period.

Additional Resources Available at www.xenotech.com:
- Webinar on Drug Metabolizing Enzymes & Transporters in NASH
- Research Biobank Donor Information Sheet and Scientific Poster

Sekisui XenoTech is a global Contract Research Organization with unparalleled experience and proven expertise from discovery through clinical support, providing cell and tissue-based products, screening, radiolabeling, API manufacturing, in vitro ADMET and pharmacology, in vivo ADMET and QWBA, metabolite ID and production, bioanalytical services and consulting.